Conditions: Relapsed Lymphomas Refractory Lymphomas
Keywords: Relapsed Lymphomas Refractory Lymphomas
Allocation: NA | Intervention model: SINGLE_GROUP
Enrollment: 17
Healthy volunteers: no

Brief summary:
The study will be a dose-finding, phase I study of the combination of vorinostat and PLD in patients with advanced lymphoma refractory to at least one prior systemic therapy.

Detailed description:
The study will also be a dose-escalating study of vorinostat 200mg to 400 mg twice daily for 7 days with PLD 30mg/m2 on day 3 every 21 days, with intrapatient dose escalation.

Primary endpoint is progression. All endpoints are observational

Arms:
arm 1: Escalating doses of vorinostat 200mg to 400mg twice daily on days 1-7, and fixed-dose IV PLD 30mg/m2 on day 3 of a 21-day cycle

Interventions: intervention 1: Vorinostat intervention 2: Pegylated Liposomal Doxorubicin (PLD), Doxil
Intervention descriptions: intervention 1: 200mg to 400 mg twice daily on days 1-7 intervention 2: IV 30mg/m2 on day 3 of a 21-day cycle

Protocol document: